Bristol-Myers Squibb's (BMY) Opdivo for Treatment of Esophageal Cancer Granted Orphan Drug Status by FDA

August 24, 2016 8:32 AM EDT

Get daily under-the-radar research with's Stealth Growth Insider Get your 2-Wk Free Trial here.

Bristol-Myers Squibb's (NYSE: BMY) Opdivo for treatment of esophageal cancer was granted orphan drug status by the FDA. The generic name is nivolumab.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Corporate News, FDA

Add Your Comment